Ponsegromab is a humanized anti-GDF15 monoclonal antibody with potential anti-cachexia activity. Ponsegromab binds to GDF15, thereby preventing the binding of GDF15 to its receptor glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL) and blocking GDF15/GFRAL-mediated signaling.